C onsidering the current emphasis on valvular heart disease in clinical practice, a mouse model of valvular regurgitation is important and timely. 1, 2 Hajj et al revisit a previously reported mouse homozygous for a single nucleotide mutation in the gene encoding the epidermal growth factor receptor (EGFR), resulting in a 90% global reduction in EGFR-tyrosine kinase activity. 3 Egfr Wa2/Wa2 , or waved-2 (Wave) mice, had been previously reported to develop abnormalities of the semilunar valves. 3 In one report, the aortic valve of Wave mice was thickened and enlarged with mixed aortic stenosis (AS)/aortic regurgitation (AR) and a mean gradient ranging from 15 to 40 mm Hg. 3 In a second, Barrick et al found that Egfr Wa2/Wa2 mice on the c57bl/6j background, in comparison to 129s1/svimj, had an increased aortic valve gradient, left ventricular hypertrophy, heart failure, and decreased survival. 4 Aortic cusp separation was not measured, but these results were again interpreted to be caused by predominantly calcific AS. 4 Both papers showed that reduced EGFR signaling was associated with the development of aortic valve disease, reflected by increased peak systolic pressure, left ventricular hypertrophy, and heart failure. 3, 4 Fortuitously, and in contrast to most models of murine congenital heart disease, animals were viable postnatally. 5 However, it remained unclear whether AS or AR was the predominant disorder.
See accompanying article on page 1653
Enter the present study by Hajj et al, who unequivocally demonstrate that Wave mice do not have AS, but are almost exclusively a model of noncalcific, myxomatous AR. 2 At 1.5 months of age, 70% of mice had moderate to severe AR and not AS. 2 This was paralleled by left ventricular hypertrophy, increased LV end diastolic dimension, and total stroke volume. Valve proteoglycan content was increased at this young age, but not calcification, demonstrating that myxomatous semilunar valves are present before the development of calcific disease. 2 Unlike the prior studies, Hajj et al used their previously validated method to measure aortic cusp separation. 6 Aortic valve separation was normal in all but 3 of 55 mice, indicating that AR, and not AS, was present and responsible for an average mean gradient of 40 mm Hg across the valve. 2 It is easy to understand how previous studies in Wave mice may have attributed such a gradient to AS; AR by itself is rarely responsible for such a large gradient in humans. However, this finding recapitulates studies from almost 30 years ago, which demonstrated that increased afterload is the predominant hemodynamic abnormality in chronic AR. [7] [8] [9] [10] Although mitral regurgitation and AR have similar increases in preload, afterload is normal in mitral regurgitation and markedly elevated in AR. 7 This explains why hearts of patients with AR are the largest known to pathologists (cor bovinum); they are an amalgam of both volume and pressure overload. Curiously, LV mass in Wave mice was similar to that found in pressure overload hypertrophy, but did not exceed them. 6 This raises the question of whether Wave mice did have an abnormality in compensatory hypertrophy. 11 More information regarding the LV geometry would have been informative; the mass to volume ratios were consistent with predominantly eccentric hypertrophy, but we do not have data concerning the wall thickness. 12 Of course, this is assuming that mice remodel in a similar fashion to humans, which is probably not the case. An additional time-point between 6 and 12 months may have helped delineate the onset of LV dysfunction. An echocardiographic or plasma biomarker that can predict this decline is highly desirable. 13 Moreover, from the data provided, we are not certain of the mechanism of LV systolic dysfunction. Although the authors speculate that contractility declined, it is still possible that any LV dysfunction observed was caused by afterload excess. In addition, the absolute level of systolic pressure, rather than the pulse pressure, would have been helpful in understanding the extent of afterload excess seen in these mice.
Certainly the valvular pathology itself is interesting (Figure) . But to what extent are myxomatous semilunar valves responsible for human AR? The data provided suggest that this mechanism is much more common than we think. It is estimated that 35% to 50% of chronic AR in adults is caused by primary valvular degeneration of unknown pathogenesis. 15 Anecdotally, we ourselves have encountered not a few cases of aortic valve diastolic prolapse or spontaneous cusp perforation (Aurigemma GP, unpublished data, 2015). Perhaps these patients have subtle abnormalities in valvular proteoglycan content that has yet to be characterized. Interestingly, progressive valvular pathology is the most common cardiac manifestation of genetic mucopolysaccharidoses. 16 Such patients have inherited defects of the enzymes required to degrade glycosoaminoglycans. Versican, the concentration of which was increased in the valves of Wave mice, is a large polymer of heparin sulfate, the same glycosoaminoglycan that accumulates abnormally in both Hurlers' and Hunters' Syndrome (MPS 1, MPS2).
Another interesting observation from the present study is that despite severe LV dilatation, mitral regurgitation was trivial or absent in all mice. 2 This could be because of compensatory growth of the mitral valve leaflets, the occurrence of which has been recently shown to occur in humans. 17, 18 There may be therapeutic opportunities to both inhibit myxomatous valve proliferation and promote normal leaflet growth, and these pathways seem to be mutually exclusive. 17 Excessive valve proteoglycan content may also serve as a nidus for lipoprotein deposition. 2 Therefore, that proteoglycan accumulation precedes valvular lipid or calcium deposition would support the practice of lowering blood cholesterol with statins in patients with AR. Likewise, it makes sense to treat patients with vasodilators to reduce valvular mechanical stress, which may prevent calcification, as the authors suggest. 2 In conclusion, like any paper of high impact, this one provides some answers but many more exciting questions (Figure) . Hajj et al have taught us a load of lessons about aortic regurgitation in mice and humans. 2 We hope that this is just the first wave of a rising tide of basic and translational data to be obtained from future mouse models of valvular heart disease.
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None. This may be as a result of decreased EGFR receptor signaling. This results in floppy, myxomatous valves, and AR in 70% of mice. The LV develops LVH, increased diastolic dimension, and increased total stroke volume; some aspects of the fetal gene program are expressed in the myocardium (ie, atrial natriuretic peptide, B-type natriuretic peptide). At 6 months of age, VICs continue to produce increased PG, and enzymes that degrade PG are reduced (ADAM metallopeptidase with thrombospondin type 1 motif, 5 [ADAMTS5]). In addition, there may be increased VIC apoptosis and transdifferentiation into fibroblasts, which promote fibrosis of the valve. Plasma lipoproteins begin to deposit on valvular PG, resulting in increased valvular lipid content; some areas of calcific change occur. The LV continues to remodel and expresses more of the fetal gene program. By 12 months of age, the valve is much more calcific. VICs are either quiescent, dead, or largely differentiated into fibroblasts. The LV systolic function has deteriorated because of either excessive afterload or contractile dysfunction; there is increased extracellular collagen production in the myocardium, and t tubules have become disrupted. ANP indicates atrial natriuretic peptide; BNP, B-type natriuretic peptide; β-MyHC, beta myosin heavy chain; Col1, Collagen 1; Col2, Collagen 2; LDL, low density lipoprotein; LV, left ventricle; LVEDV, left ventricular end diastolic volume; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; MCIP-1.4, myocyte-enriched calcineurin-interacting protein 1.4; PCD, programmed cell death; PG, proteoglycan; VIC, valvular interstitial cell; and SV, stroke volume.
